Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Viral Immunol ; 36(6): 429-434, 2023.
Article in English | MEDLINE | ID: mdl-37102675

ABSTRACT

We determined anti-rubella and anti-measles immunoglobulin G (IgG) in 7- to 19-year-old children and adolescents with vaccine only-induced immunity of Córdoba, Argentina, during a 6-month period over 2021-2022. Of the 180 individuals studied, 92.2% and 88.3% were positive for anti-measles and anti-rubella IgG, respectively. No significant differences were found comparing anti-rubella IgG concentrations (p = 0.144) and anti-measles IgG concentrations (p = 0.105) of individuals classified by age, but anti-measles IgG and anti-rubella IgG levels were significantly higher among female individuals compared with males (p = 0.031 and p = 0.036, respectively). Female subjects in the younger age group had higher concentrations of anti-rubella IgG as well (p = 0.020), even when anti-measles IgG concentrations did not differ among female age-subgroups (p = 0.187). In contrast, age subgroups of male individuals did not have significantly different IgG concentrations for rubella (p = 0.745) or measles (p = 0.124). Among samples with discordant results (22/180, 12.6%), 9.1% were negative for rubella but positive for measles; 13.6% were equivocal for rubella and positive for measles; 22.7% were equivocal for rubella and negative for measles, while 54.5% were positive for rubella but negative for measles. The findings indicate a seroprevalence below recommended for preventing measles in the population studied, while they evidence the need for standardization of serological tests for rubella IgG.


Subject(s)
Measles , Mumps , Rubella , Humans , Child , Male , Female , Adolescent , Young Adult , Adult , Seroepidemiologic Studies , Argentina/epidemiology , Antibodies, Viral , Rubella/epidemiology , Rubella/prevention & control , Measles/epidemiology , Measles/prevention & control , Measles-Mumps-Rubella Vaccine , Immunoglobulin G , Mumps/epidemiology , Mumps/prevention & control
2.
Access Microbiol ; 4(10): acmi000428, 2022.
Article in English | MEDLINE | ID: mdl-36415736

ABSTRACT

Human parvovirus B19 (B19V) is the aetiological agent of erythema infectiosum. Primary infection during pregnancy can be transmitted to the foetus and cause foetal abnormalities related to depletion of erythrocyte progenitor cells, including congenital anaemia, hydrops, and foetal death. In this paper we report the detection of B19V infection in a pregnant patient, which onset occurred without appreciable signs and symptoms until she developed inappropriate contractions for gestational age and fluid loss. B19V infection resulted in severe hydrops fetalis with a fatal course for the foetus, while persisted in the mother at least 12 months after foetal death. The objective of this report is to highlight the importance of optimizing B19V diagnosis through early suspicion and testing during pregnancy. Knowing the mother's immune status before or at the beginning of gestation can contribute, together with early diagnosis, to improve the management of patients at risk.

3.
J Med Microbiol ; 71(10)2022 Oct.
Article in English | MEDLINE | ID: mdl-36301612

ABSTRACT

Introduction. Human bocavirus 1 (HBoV1) infection occurs with viral genome presence in respiratory secretions (RS) and serum, and therefore both samples can be used for diagnosis.Gap statement. The diagnostic sensitivity of HBoV1 DNA detection in serum and the duration of DNAaemia in severe clinical cases have not been elucidated.Aim. To determine HBoV1 DNA in serum and RS of paediatric patients hospitalized for lower acute respiratory infection (LARI) and to analyse the clinical-epidemiological features of positive cases.Methodology. This was a prospective, transverse study. Physicians selected the clinical situations and obtained paired clinical samples (RS and serum) that were tested by PCR/qPCR for HBoV1. Positive cases were analysed considering time of specimen collection, co-detection, clinical manifestations and viral load; statistical significant level was set at α=0.05.Results. HBoV1 was detected in 98 of 402 cases included (24 %); 18/98 (18 %) patients had the virus detectable in serum and 91/98 (93 %) in RS (P<0.001). Positivity rates were not significantly different in patients with RS and serum collected within or beyond 24 h of admission. Single HBoV1 infection was identified in 39/98 patients (40 %), three patients had HBoV1 in both clinical samples (3/39, 8 %) and 32 (32/39, 82 %) only in RS, 22 of them (69 %) with both clinical samples within 24 h of admission. Cough (P=0.001) and rhinitis (P=0.003) were significantly frequent among them and most patients were diagnosed with bronchiolitis (22/39, 56 %) and pneumonia (9/39, 23 %), which was more frequent compared to cases with co-infection (P=0.04). No significant differences were identified among patients with high, medium or low viral load of HBoV1 regarding rate of positivity in both clinical samples, the time of collection of RS and serum, co-detection, first episode of LARI, clinical manifestations, comorbidity or requirement for assisted ventilation. Intensive care unit (ICU) patients had a significantly higher frequency of detection (P<0.001) and co-detection (P=0.001) compared to patients on standard care.Conclusions. HBoV1 is prevalent among infant patients hospitalized for LARI and including it in the standard testing can add to the aetiological diagnosis in these cases, especially for patients admitted to the ICU. HBoV1 detection in serum did not contribute significantly to the diagnosis as compared to detection in respiratory secretions.


Subject(s)
Human bocavirus , Parvoviridae Infections , Respiratory Tract Infections , Infant , Humans , Child , Human bocavirus/genetics , Prospective Studies , Parvoviridae Infections/diagnosis , Respiratory Tract Infections/diagnosis , Real-Time Polymerase Chain Reaction
4.
Heliyon ; 6(5): e03869, 2020 May.
Article in English | MEDLINE | ID: mdl-32395652

ABSTRACT

A retrospective, cross-sectional study was conducted to determine the frequency of human parvovirus B19 (B19V) infected individuals, viral loads and immunity among blood donors from Argentina, in a post-epidemic outbreak period. B19V DNA and specific IgG were tested in minimum study samples of donors attending a blood bank at Córdoba, Argentina, in 2014. Anti-B19V IgM and viral loads were determined in B19V-positive plasma samples. Seven of 731 samples (0.96%) resulted positive, corresponding to individuals aged 32-53 years, four of them repeat donnors and three first-time donors. Viral loads were <103 IU/mL. None had IgM and 6/7 had IgG, one of them at a high level (in the range of 100-200 IU/ml, and the remaining 5 at low to medium level, 5-50 IU/ml). Thus one case was classified as acute infection (DNA+/IgM-/IgG-) and six as potentially persistent infections (DNA+/IgM-/IgG+). No coinfections with other pathogens of mandatory control in the pre-transfusion screening were detected. Prevalence of IgG was 77.9% (279/358). This study provides the first data of B19V prevalence in blood donors in Argentina, demonstrating high rates of acute and persistent B19V infections and high prevalence of anti-B19V IgG in a post-epidemic period. Further research is needed to elucidate mechanisms/factors for B19V persistence as well as follow-up of recipients in the context of haemo-surveillance programs, contributing to the knowledge of B19V and blood transfusion safety.

5.
Access Microbiol ; 1(5): e000037, 2019.
Article in English | MEDLINE | ID: mdl-32974527

ABSTRACT

INTRODUCTION: B19 virus (B19V) and bocavirus 1 (HBoV1) are human pathogenic parvoviruses that are prevalent worldwide and are responsible for a diverse and not yet fully established spectrum of clinical manifestations. OBJECTIVE: To screen B19V and HBoV1 in patients with clinical manifestations associated with acquisition of the infection during gestation. METHODS: A retrospective, observational study was performed that included serum samples from patients without a previous known aetiology. B19V and HBoV1 were determined by end-point PCR. Positive samples were genotyped. RESULTS: A total of 106 serum samples were analysed, 61 from pregnant women and 45 from neonates and paediatric patients. None were positive for HBoV1, while B19V was detected in 37/106 [34.9 %, 95 % confidence interval (CI): 26.5-44.4] of the samples studied. In the group of pregnant women, 28/61 (45.9 %, 95 % CI: 34.0-58.3) were B19V-positive, and 2 of them had foetal anaemia followed by hydrops and foetal death, 3 were associated with a history of recurrent pregnancy loss and there was 1 case of spontaneous abortion. B19V was also detected in cases of maternal febrile exanthema, polyhydramnios, oligohydramnios and foetal ascites. In the group of children, 9/45 (20.0 %, 95 % CI: 10.9-33.8) neonatal patients were B19V-positive, and this was associated with foetal hydrops, TORCH syndrome and cardiac alterations. The nucleotide sequences analysed confirmed the identity of B19V genotype 1. CONCLUSIONS: We found no evidence to indicate the presence of HBoV1 in maternal blood or in the newborns/paediatric patients (hence providing no support for the supposed vertical transmission). On the other hand, the high frequency of B19V in the pathologies studied indicates the importance of molecular diagnosis in both the mother and the child. Future efforts should contribute to early detection and characterization of infections.

6.
J Med Microbiol ; 66(12): 1715-1721, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29095139

ABSTRACT

PURPOSE: Human parvovirus B19 (B19V) can cause anemia in immunocompromised patients. We aimed to investigate the presence of B19V in HIV+ adults with different CD4+ T cell counts, to recognise the frequency of B19V in these different conditions and its possible association with anemia. METHODOLOGY: We studied B19V specific IgM, IgG and DNA in 98 HIV+ patients and in 52 healthy individuals. HIV load, CD4+ counts and haemoglobin level were also determined in the patients. RESULTS: No individual in the control group had detectable IgM, 41/52 (78.8 %) had IgG and 5/52 (9.6 %) had B19V DNA. Among HIV+ patients, we found 5/98 (5.1 %) IgM+, 66/98 (67.3 %) IgG+ and 15/98 (15.3 %) had B19V DNA (no significant differences between the two groups compared). Considering the CD4+ cell range in HIV patients, 37 had <200 CD4+ cells ml-1, 31 had 200-500, and 30 had >500. Anti-B19V IgG prevalence in patients with >500 CD4+ cells ml-1 was significantly higher than in the rest (P=0.004) and compared to the control (P=0.046). B19V DNA concentration was always <103 IU ml-1, including 5 healthy individuals and 15 HIV+ patients. There was no significant association between B19V IgM or DNA and anemia nor between B19V DNA and HIV load. CONCLUSIONS: The results indicate that B19V is not a high-risk factor for anemia in adult HIV+ patients under HAART treatment. Further studies will contribute to elucidate the mechanisms and significance of B19V DNA prevalence/persistence in adults, independently of the CD4+ cell status.


Subject(s)
CD4 Lymphocyte Count , HIV Infections/virology , Parvoviridae Infections/diagnosis , Parvovirus B19, Human/isolation & purification , Adolescent , Adult , Aged , Anemia/diagnosis , Anemia/virology , Antibodies, Viral/blood , Antiretroviral Therapy, Highly Active , Case-Control Studies , Coinfection/virology , DNA, Viral/blood , Female , HIV Infections/drug therapy , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Middle Aged , Parvoviridae Infections/blood , Retrospective Studies , Viral Load , Young Adult
7.
Córdoba; s.n; 2017. 99 p. tab, graf.
Thesis in Spanish | LILACS | ID: biblio-983092

ABSTRACT

RESUMEN: El parvovirus B19 (B19V), descubierto en 1974, es un patógeno humano de distribución global. Si bien su infección puede transcurrir de manera asintomática, es conocido por ser capaz de causar un amplio espectro de manifestaciones clínicas como son el eritema infeccioso, artropatías, crisis aplásica en individuos con recambio acelerado de glóbulos rojos por una enfermedad de base, y anemia crónica en inmunocomprometidos, entre otras patologías en las que aún se investiga la causalidad del B19V. La infección durante el embarazo es un riesgo potencial para el feto...


ABSTRACT: Parvovirus B19 (B19V), discovered in 1974, is a pathogen of global distribution. While the infection can be asymptomatic, it is known for being able to cause a wide range of clinical manifestations such as erythema infectiosum (or fitth disease), arthropathy, aplastic crisis in persons with accelerated red blood cell renewal due to a base disease, and chronic anemia in immunocompromised individuals, among other pathologies inwhich B19V causality is still under research. In addition, infection during pregnancy is a potential risk for the fetus...


Subject(s)
Male , Female , Humans , Biomarkers, Pharmacological/analysis , Parvoviridae Infections/diagnosis , Parvoviridae Infections/immunology , /immunology , Argentina/epidemiology
8.
Braz J Infect Dis ; 16(1): 38-44, 2012.
Article in English | MEDLINE | ID: mdl-22358354

ABSTRACT

UNLABELLED: Human bocavirus (HBoV) is a parvovirus whose association with respiratory disease is currently under investigation. OBJECTIVE: To determine HBoV prevalence in children with lower acute respiratory infection. METHODS: We investigated HBoV in 433 nasopharyngeal aspirates collected in 2007-2009 from children 0 to 5 years old hospitalized with bronchiolitis or pneumonia in Córdoba, Argentina. RESULTS: The general prevalence of HBoV was 21.5% and the positive cases (HBoV+) were more frequent during winter and spring. The mean age of HBoV+ patients was 6.9 months, with 87.1% of the detections corresponding to infants less than 1 year old (among which the prevalence of HBoV was 26.3% in patients < 3 months of age, 22.1% in 3 to 6 months, 25.3% in 6 to 9 months, and 18.8% in 9 to 12 months). The sequence analysis of the NP1 coding region of 15 isolates showed that all isolates from Cordoba were HBoV1 which exhibited a homology of nearly 100% both among themselves and with the originally discovered virus from 2005. CONCLUSION: Overall, our results indicate that HBoV is a significant pathogen that contributes to acute respiratory infection both on its own and during coinfection with other viruses.


Subject(s)
Bronchiolitis, Viral/virology , Human bocavirus , Parvoviridae Infections/virology , Pneumonia, Viral/virology , Acute Disease , Argentina/epidemiology , Bronchiolitis, Viral/epidemiology , Child, Preschool , DNA, Viral/analysis , Female , Human bocavirus/genetics , Human bocavirus/isolation & purification , Humans , Infant , Infant, Newborn , Male , Nasopharynx/virology , Parvoviridae Infections/epidemiology , Phylogeny , Pneumonia, Viral/epidemiology , Polymerase Chain Reaction , Prevalence
9.
Braz. j. infect. dis ; 16(1): 38-44, Jan.-Feb. 2012. ilus, tab
Article in English | LILACS | ID: lil-614548

ABSTRACT

Human bocavirus (HBoV) is a parvovirus whose association with respiratory disease is currently under investigation. OBJECTIVE: To determine HBoV prevalence in children with lower acute respiratory infection. METHODS: We investigated HBoV in 433 nasopharyngeal aspirates collected in 2007-2009 from children 0 to 5 years old hospitalized with bronchiolitis or pneumonia in Córdoba, Argentina. RESULTS: The general prevalence of HBoV was 21.5 percent and the positive cases (HBoV+) were more frequent during winter and spring. The mean age of HBoV+ patients was 6.9 months, with 87.1 percent of the detections corresponding to infants less than 1 year old (among which the prevalence of HBoV was 26.3 percent in patients < 3 months of age, 22.1 percent in 3 to 6 months, 25.3 percent in 6 to 9 months, and 18.8 percent in 9 to 12 months). The sequence analysis of the NP1 coding region of 15 isolates showed that all isolates from Cordoba were HBoV1 which exhibited a homology of nearly 100 percent both among themselves and with the originally discovered virus from 2005. CONCLUSION: Overall, our results indicate that HBoV is a significant pathogen that contributes to acute respiratory infection both on its own and during coinfection with other viruses.


Subject(s)
Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Bronchiolitis, Viral/virology , Human bocavirus , Parvoviridae Infections/virology , Pneumonia, Viral/virology , Acute Disease , Argentina/epidemiology , Bronchiolitis, Viral/epidemiology , DNA, Viral/analysis , Human bocavirus/genetics , Human bocavirus/isolation & purification , Nasopharynx/virology , Phylogeny , Polymerase Chain Reaction , Prevalence , Parvoviridae Infections/epidemiology , Pneumonia, Viral/epidemiology
10.
Enferm Infecc Microbiol Clin ; 24(2): 81-5, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16545314

ABSTRACT

BACKGROUND: Atherosclerosis is pathogenically similar to a chronic inflammatory response. Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis. Chlamydophila pneumoniae has been suggested to play a role in the origin of PAD. OBJECTIVE: To determine whether C. pneumoniae is present in atherosclerosis lesions of the carotid artery wall in patients with PAD through several diagnostic methods and to characterize C. pneumoniae susceptibility profiles. METHODS: The presence of C. pneumoniae in 9 tissue samples from atherosclerotic lesions obtained by carotid endarterectomy was investigated by 3 methods. Karnofsky-fixed specimens were examined by transmission electron microscopy (TEM), isolation of C. pneumoniae was attempted in LLCMK2 cell structure (ICC), and the presence of chlamydial DNA was investigated by polymerase chain reaction (PCR). The in vitro activities of azithromycin, roxithromycin and penicillin were tested in 4 isolations and the reference strain of C. pneumoniae (AR39). RESULTS: C. pneumoniae was detected in atherosclerotic plaques from 4 patients with PAD. The pathogen was identified by TEM, PCR and ICC. We report data of the in vitro susceptibility of 4 strains. These strains did not differ from respiratory AR39 strain in their susceptibility patterns to azithromycin, roxithromycin and penicillin. CONCLUSIONS: C. pneumoniae is frequently found in the advanced carotid atherosclerotic lesions of patients undergoing endarterectomy. Although these findings do not establish causality in carotid artery atherosclerosis, they should stimulate investigation of the possible causal or pathogenic role of C. pneumoniae. Notably, the profiles of antibiotic susceptibility of C. pneumoniae isolated from 4 of the patients did not differ from those of the reference strain.


Subject(s)
Anti-Bacterial Agents/pharmacology , Atherosclerosis/microbiology , Carotid Stenosis/microbiology , Chlamydophila pneumoniae/drug effects , Chlamydophila pneumoniae/isolation & purification , Azithromycin/pharmacology , Drug Resistance, Bacterial , Humans , Microbial Sensitivity Tests , Penicillins/pharmacology , Roxithromycin/pharmacology
12.
Viral Immunol ; 17(1): 87-100, 2004.
Article in English | MEDLINE | ID: mdl-15018665

ABSTRACT

Congenital rubella is a persistent infection that contrasts with acute postnatal infection. Basis of the Rubella virus (RV) persistence still remain unknown, though several hypotheses have been postulated. RV induces apoptosis in cell lines, maybe as a way of cell-autonomous defense mechanism against virus. Considering the pattern of c-oncogenes expression during embryogenesis, which promotes proliferation while it inhibits apoptosis in specific cells, at certain times, it can be proposed that when RV infection establishes early in gestation, embryo cells that are proliferating have their apoptotic pathways shut down; then infected proliferating embryo cells cannot execute their apoptotic death program. We here report that RV induces apoptosis in human normal-term placenta chorionic villi explants (CVE) and in monolayers of cytotrophoblasts (CTB), but does not induce apoptosis in primary human embryo fibroblasts (HEF) cultures. These results suggest distinct responses to RV infection when comparing differentiated cells, as CTB, to cells with high proliferating potential, as HEF. RV shoots apoptosis in the former, whereas in fibroblastic dividing cells derived from embryo, RV appears not to be enough stimulus to activate the genetic program of cell death.


Subject(s)
Apoptosis , Embryo, Mammalian/cytology , Embryo, Mammalian/virology , Fibroblasts/virology , Rubella virus/physiology , Animals , Cells, Cultured , Chlorocebus aethiops , Chorionic Villi/virology , Cytopathogenic Effect, Viral , Humans , Organ Culture Techniques , Placenta , Trophoblasts/virology , Vero Cells
13.
Acta bioquím. clín. latinoam ; 35(4): 475-478, dic. 2001.
Article in Spanish | BINACIS | ID: bin-8797

ABSTRACT

Durante el período 1999-2000, se realizó el aislamiento de Chlamydia trachomatis (C trachomatis) a partir de 132 muestras genitales de una población seleccionada de la ciudad de Córdoba. Las inclusiones chlamydiales se revelaron por coloración de Lugol y por inmunofluorescencia indirecta con anticuerpos monoclonales (IFI-AcMn). Se obtuvieron 43 aislamientos positivos por IFI-AcMn, en cambio, sólo 40 fueron positivos por coloración de Lugol. Los 3 aislamientos IFI positivos y Lugol negativos desarrollaron inclusiones semejantes a las inclusiones chlamydiales, pero en su interior no habían retenido el colorante con iodo. Si como los resultados demuestran, existen cepas de C. trachomatis con nuevas características, el aislamiento en cultivo celular y el revelado por IFI-AcMn sería el método de elección para el diagnóstico de la infección por C. trachomatis (AU)


Subject(s)
Humans , Chlamydia trachomatis/isolation & purification , Chlamydia Infections/diagnosis , Clinical Laboratory Techniques , Antibodies, Monoclonal , Fluorescent Antibody Technique, Indirect
14.
Acta bioquím. clín. latinoam ; 35(4): 475-478, dic. 2001.
Article in Spanish | LILACS | ID: lil-305647

ABSTRACT

Durante el período 1999-2000, se realizó el aislamiento de Chlamydia trachomatis (C trachomatis) a partir de 132 muestras genitales de una población seleccionada de la ciudad de Córdoba. Las inclusiones chlamydiales se revelaron por coloración de Lugol y por inmunofluorescencia indirecta con anticuerpos monoclonales (IFI-AcMn). Se obtuvieron 43 aislamientos positivos por IFI-AcMn, en cambio, sólo 40 fueron positivos por coloración de Lugol. Los 3 aislamientos IFI positivos y Lugol negativos desarrollaron inclusiones semejantes a las inclusiones chlamydiales, pero en su interior no habían retenido el colorante con iodo. Si como los resultados demuestran, existen cepas de C. trachomatis con nuevas características, el aislamiento en cultivo celular y el revelado por IFI-AcMn sería el método de elección para el diagnóstico de la infección por C. trachomatis


Subject(s)
Humans , Chlamydia Infections , Chlamydia trachomatis , Antibodies, Monoclonal , Clinical Laboratory Techniques , Fluorescent Antibody Technique, Indirect
SELECTION OF CITATIONS
SEARCH DETAIL
...